DETAILED ACTION
Notice of Pre-AIA or AIA Status
This Office action is based on the 18/727,055 application filed 5 July 2024, which is being examined under the first inventor to file provisions of the AIA .
Claims 1-22 are pending and have been fully considered.
Claim Interpretation
Applicant is reminded that “[i]f the body of a claim fully and intrinsically sets forth all of the limitations of the claimed invention, and the preamble merely states, for example, the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention’s limitations, then the preamble is not considered a limitation and is of no significance to claim construction.” Shoes by Firebug LLC v. Stride Rite Children’s Grp., LLC, 962 F.3d 1362, 2020 USPQ2d 10701. In the instant case, an oxygen-absorbing adhesive in the preamble reciting “[a]n oxygen-absorbing adhesive composition comprising…” and an oxygen-absorbing coating agent in the preamble reciting “[a]n oxygen-absorbing coating agent composition…” merely states the purpose or intended use of the invention(s) and is of no significance to claim construction. The limitations of the composition are fully and intrinsically set forth in the body of the claim, namely, the compound according to claim 1 and an oxidation promoting catalyst.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1-8 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Bartlett et al (US 2,875,244).
PNG
media_image1.png
115
341
media_image1.png
Greyscale
With respect to claims 1-2 and 8, Bartlett et al discloses “[i]t is the main object of the present invention to provide dicarboxylic acid derivatives of dicyclopentadiene and its homologs, as well as a new method for their preparation…It has now been discovered that novel dicarboxylic acids can be advantageously prepared by first hydrating the dicyclopentadiene to provide an unsaturated secondary alcohol” [column 1, lines 29-38].
The unsaturated secondary alcohol (or unsaturated sec. C10 alcohol) corresponds to the oxygen-absorbing compound having one unsaturated five-membered ring and an organic group 1 with a function group having active hydrogen, particularly, an aliphatic hydroxyl group [compare the hydroxyl (-OH) group in the structure above to the disclosure in paragraph 0084 of the published application]. The unsaturated sec. C10 alcohol also has a molecular structure that is a subset or species of Chemical Formula 1 in instant claim 8.
With respect to claims 3-7, note that claim 1 recites the organic group 2 in the alternative only.
Claim(s) 1-8, 10-13, and 17-19 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Teshigawara et al (JP 1993213919).
With respect to claims 1-2, 8, 10-12, and 17-18, Teshigawara et al discloses “[t]o a 200 ml four-necked flask with a cooler, a stirring device, and a thermometer, 12.0 g of 31% hydrogen peroxide solution (110.4 mmol in terms of H2O2) and 250 mg (H2WO4, 1 mmol) of tungstic acid were charged and dissolved at 60° C. After cooling to room temperature, 62 mg of 85% phosphoric acid was added. To this, 120 mg of cetylpyridinium chloride and 13.6 g of hydroxydicyclopentadiene (DCPD-OH, 92 mmol) were added to 100 ml of chloroform and reacted at 30°C for 1 hour” [Example 1, paragraph 0046]. The hydroxydicyclopentadiene corresponds to the oxygen-absorbing compound having one unsaturated five-membered ring and an organic group 1 with a function group having active hydrogen, particularly, an aliphatic hydroxyl group. The hydroxydicyclopentadiene has a molecular structure depicted by general formula (III) [Chemical 9, paragraph 0024]:
PNG
media_image2.png
65
96
media_image2.png
Greyscale
The hydrogen peroxide corresponds to oxidation promoting catalyst of instant claims 10 and 11.
With respect to claims 3-7, note that claim 1 recites the organic group 2 in the alternative only.
With respect to claims 13 and 19, note that the compound composed/including a cation composed of a transition metal is recited in the alternative only in instant claims 12 and 18 from which 13 and 19 depend, respectively.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claim(s) 14-15 and 20-21 is/are rejected under 35 U.S.C. 103 as being unpatentable over Teshigawara et al (JP 1993213919, which is equivalent to JP H05213919).
Note: in the discussion that follows, reference will be made to the English language machine translation of JP 1993213919 provided by the World Intellectual Property Organization (WIPO), which reference appears to be equivalent to the ‘919 reference.
With respect to claims 14 and 20, note that in addition to hydroxydicyclopentadiene, other exemplary compounds include [general formula (III) (Chemical 9), paragraph 0024]:
PNG
media_image3.png
60
120
media_image3.png
Greyscale
The compound depicted above is clearly a hydroxyl-group containing compound.
At the time of the effective filing date of the instant application, it would have been obvious to one of ordinary skill in the art to modify the hydroxydicyclopentadiene reactant with the diol above because “[i]t is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose…[T]he idea of combining them flows logically from their having been individually taught in the prior art.” In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072. Therefore, the invention as a whole would have been prima facie obvious.
With respect to claims 15 and 21, the isocyanate-based compound is recited in the alternative in claims 14 and 20 from which 15 and 21 depend, respectively.
Allowable Subject Matter
Claims 9, 16, and 22 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
The following is a statement of reasons for the indication of allowable subject matter: the prior art does not appear to anticipate or render obvious the compound represented by formula (5) nor the recited hydroxyl-group containing compounds in instant claims 16 and 22.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN A MCCAIG whose telephone number is (571)270-5548. The examiner can normally be reached Monday to Friday 8 to 4:30 Mountain Time.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, In Suk Bullock can be reached at 571-272-5954. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/BRIAN A MCCAIG/Primary Examiner, Art Unit 1772
22 October 2026